argus

Marksans Pharma Ltd.

NSE: MARKSANSINE750C01026₹14,612 Cr

Timeline

Time (IST)TypeMEventSrc
13 Nov, 07:29 pm—…Marksans Pharma Ltd - 524404 - Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended 30 September 2025bse
10 Nov, 02:45 pm—…Marksans Pharma Limited has informed the Exchange regarding 'Observance of Vigilance Awareness Week 2025' and appealed to all shareholders and other stakeholders to take e-pledge.nse
10 Nov, 12:19 pm—…Marksans Pharma Limited has informed the Exchange regarding a press release dated November 10, 2025, titled " US FDA cGMP inspection at Company s 2nd manufacturing facility located at Plot No. A-1, Phase 1-A, Verna Industrial Estate, Verna, Goa, India concluded with zero Form 483 observation.".nse
10 Nov, 12:05 pm—…Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
05 Nov, 09:18 am—…Marksans Pharma Limited has informed the Exchange regarding a press release dated November 05, 2025, titled "Marksans Pharma Limited s wholly owned subsidiary in UK, Relonchem Limited receives Marketing Authorization for its product Exemestane 25mg film-coated tablet.".nse
05 Nov, 09:10 am—…Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
03 Nov, 12:17 pm—…Marksans Pharma Limited has informed the Exchange regarding 'DISCLOSURE UNDER 100 DAY CAMPAIGN - "SAKSHAM NIVESHAK"'.nse
31 Oct, 11:49 am—…Marksans Pharma Limited has informed the Exchange about Schedule of a conference call for analysts and investors on Friday, November 14, 2025 at 05:00 PM (IST) to discuss the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2025.nse
27 Oct, 10:35 am—…Marksans Pharma Limited has informed the Exchange about voluntary ESG rating assigned by CFC Finlease Private Limited.nse
23 Oct, 04:59 pm—…Marksans Pharma Ltd - 524404 - Board Meeting Intimation for Declaration Of Quarterly Results For The Quarter And Nine Months Ended September 30, 2025bse
15 Oct, 02:06 pm—…Marksans Pharma Limited has informed the Exchange regarding a press release dated October 15, 2025, titled "Marksans Pharma Ltd's wholly owned subsidiary Relonchem Limited receives Marketing Authorisation for its products from UK MHRA".nse
15 Oct, 01:54 pm—…Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
08 Oct, 11:03 am—…Marksans Pharma Limited has informed the Exchange about Credit Rating- Othersnse
08 Oct, 10:53 am—…Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Credit Ratingbse
06 Oct, 03:10 pm—…Marksans Pharma Limited has informed the Exchange regarding 'DISCLOSURE REGARDING 100 DAY CAMPAIGN - "SAKSHAM NIVESHAK"'.nse
24 Sept, 04:59 pm—…Marksans Pharma Limited has informed the Exchange about General Updates regarding the Nomination and Remuneration Committee (the designated Compensation Committee) of the Company has, today i.e., September 24, 2025, approved grant of 4,00,000 (Four Lakh) Stock Options to the certain eligible employees of the Company and its subsidiaries under Marksans Employees Stock Option Scheme 2024.nse
24 Sept, 04:57 pm—…Marksans Pharma Limited has informed the Exchange about Options to purchase securities under Marksans Employees Stock Option Scheme 2024 ( Scheme )nse
23 Sept, 02:18 pm—…Marksans Pharma Limited has informed the Exchange regarding a press release dated September 23, 2025, titled "Marksans Pharma Ltd's subsidiary Relonchem Limited in UK received marketing authorisation for its products from UK MHRA.".nse
23 Sept, 02:10 pm—…Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
16 Sept, 12:10 pm—…Marksans Pharma Limited has informed the Exchange regarding '100 DAY CAMPAIGN - "SAKSHAM NIVESHAK"'.nse